Radiation is considered one of the most powerful methods of destroying cancer for over a century. But even today, ways to deliver significant doses to a tumor without damaging normal surrounding tissue are few. We are breaking that barrier with our new class of targeted radiotherapeutics.
Leveraging novel drug formulations and technologies, our drugs are designed to deliver a single, safe and effective dose of radiation directly to the tumor in adults and children battling rare and difficult-to-treat cancers. Our precise approach has the potential to preserve normal cell and tissue functioning – and add more precious moments to each patient’s life.
Combining innovative formulations with novel administration techniques, we can potentially insert a single radiation dose into just the tumor or affected tissue until the radiation dissipates and is safely cleared by the body.
We have developed an innovative approach to encapsulating the radiation particle, Rhenium, and administering it in elevated doses that are potentially retained for long enough to overwhelm and potentially eliminate tumor cells.
Rhenium radioisotopes emit relatively short-range beta rays for precisely targeting tumors, as well as gamma rays for live imaging throughout treatment.
We have patents describing proprietary techniques for transporting and trapping isotopic Rhenium into nanoliposomes using a lipophilic chelator, BMEDA, for radionuclide therapy.
Nanoliposomes are a safe and reliable way to encapsulate, deliver and retain radiation within a specific injection site.
We load radiolabeled nanoliposomes into biodegradable, embolic, alginate microspheres to create a novel delivery system.
The first Rhenium-186 radiolabeled nanoliposome therapy, designed to target brain and CNS cancers in adults and children, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
A next-generation radioembolization therapy in which thousands of Rhenium-188 radiolabeled nanoliposomes are loaded into a single alginate microsphere to potentially treat a multitude of solid organ cancers, including two forms of liver cancer, hepatocellular carcinoma and metastatic colorectal cancer.
